Dynamic susceptibility contrast perfusion MRI helps in differentiating double-expressor from non-double-expressor subtypes in primary central nervous system lymphoma
Neuroradiology · 2025
DOI: 10.1007/s00234-024-03511-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuroradiology, 2025. Verfasst von Goh Sasaki und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic Radiology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan. Hauptthemen laut MEDLINE: Central Nervous System Neoplasms, Lymphoma, Magnetic Resonance Angiography, Magnetic Resonance Imaging. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: In the 2016 WHO Classification of Lymphoid Tissue Neoplasms, co-expression of MYC and BCL2 is newly designated as double expressor lymphoma. Patients with primary central nervous system lymphoma with double expressor (DE-PCNSL) have been reported to have a higher risk of recurrence and a worse prognosis than those with PCNSL without double expressor (non-DE-PCNSL). The aim of this study was to determine whether DE-PCNSL has characteristic clinical and MR imaging features compared to non-DE-PCNSL. METHODS: This study included 36 immunocompetent patients with PCNSL, including 16 with double expressor and 20 without double expressor. The enhancement pattern and the values of apparent diffusion coefficient (ADC), relative cerebral blood volume (rCBV), leakage-corrected rCBV, and K2 at enhancing lesions were compared between the DE-PCNSL and non-DE-PCNSL groups. The mean and minimum values from the ROI on ADC maps were designated as ADCmean and ADCmin, respectively. The data of rCBV, leakage-corrected rCBV and K2 were obtained from dynamic susceptibility contrast (DSC) perfusion MRI. The Kaplan-Meier method was used to estimate progression-free survival (PFS) differences. RESULTS: DE-PCNSL was significantly more common in women (12 of 16 patients, 75%) compared to non-DE-PCNSL (7 of 20 patients, 35%; P =.02). The rCBV ratio and leakage-corrected rCBV ratio were significantly lower in DE-PCNSL compared to non-DE-PCNSL (P =.02 and P =.03, respectively). There was no significant difference in the enhancement pattern and ADCmean, ADCmin and K2 values between the two groups. DE-PCNSL tended to have a shorter PFS than non-DE-PCNSL, although the difference was not significant. CONCLUSION: rCBV and leakage-corrected rCBV may help differentiate double-expressor from non-double-expressor subtypes in PCNSL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Diagnostic Radiology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
- Department of Diagnostic Radiology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan. hama-moto@hotmail.co.jp.
- Department of Neurosurgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
- Department of Radiology, Weill Cornell Medicine, New York, NY, USA.
Zitieren
APA
Sasaki, G., Uetani, H., Kuroda, J. I., Kitajima, M., Ishiuchi, S., Sato, K., Wang, Y., Mukasa, A., & Hirai, T. (2025). Dynamic susceptibility contrast perfusion MRI helps in differentiating double-expressor from non-double-expressor subtypes in primary central nervous system lymphoma. Neuroradiology. https://doi.org/10.1007/s00234-024-03511-y
Vancouver
Sasaki G, Uetani H, Kuroda JI, Kitajima M, Ishiuchi S, Sato K, et al. Dynamic susceptibility contrast perfusion MRI helps in differentiating double-expressor from non-double-expressor subtypes in primary central nervous system lymphoma. Neuroradiology. 2025. doi:10.1007/s00234-024-03511-y
BibTeX
@article{Sasaki2025,
author = {Sasaki, Goh and Uetani, Hiroyuki and Kuroda, Jun-Ichiro and Kitajima, Mika and Ishiuchi, Soichiro and Sato, Kanako and Wang, Yi and Mukasa, Akitake and Hirai, Toshinori},
title = {Dynamic susceptibility contrast perfusion MRI helps in differentiating double-expressor from non-double-expressor subtypes in primary central nervous system lymphoma},
journal = {Neuroradiology},
year = {2025},
doi = {10.1007/s00234-024-03511-y}
}
EUVIMED